Literature DB >> 11832527

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

William C Knowler1, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan.   

Abstract

BACKGROUND: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.
METHODS: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups.
RESULTS: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin.
CONCLUSIONS: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832527      PMCID: PMC1370926          DOI: 10.1056/NEJMoa012512

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  20 in total

1.  Changing habits to delay diabetes.

Authors:  P A Tataranni; C Bogardus
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

2.  The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

Authors: 
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study.

Authors:  F de Vegt; J M Dekker; A Jager; E Hienkens; P J Kostense; C D Stehouwer; G Nijpels; L M Bouter; R J Heine
Journal:  JAMA       Date:  2001-04-25       Impact factor: 56.272

5.  Implementation of group sequential logrank tests in a maximum duration trial.

Authors:  K K Lan; J M Lachin
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

6.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

7.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

8.  Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies.

Authors:  S L Edelstein; W C Knowler; R P Bain; R Andres; E L Barrett-Connor; G K Dowse; S M Haffner; D J Pettitt; J D Sorkin; D C Muller; V R Collins; R F Hamman
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

9.  Trends in the prevalence and incidence of self-reported diabetes mellitus -- United States, 1980-1994.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-10-31       Impact factor: 17.586

Review 10.  Preventing non-insulin-dependent diabetes.

Authors:  W C Knowler; K M Narayan; R L Hanson; R G Nelson; P H Bennett; J Tuomilehto; B Scherstén; D J Pettitt
Journal:  Diabetes       Date:  1995-05       Impact factor: 9.461

View more
  2000 in total

Review 1.  Type 2 diabetes in children and youth.

Authors:  Francine Ratner Kaufman
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  The emerging science of body weight regulation and its impact on obesity treatment.

Authors:  Judith Korner; Louis J Aronne
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.

Authors:  Y E Lentferink; C A J Knibbe; M M J van der Vorst
Journal:  Drugs       Date:  2018-12       Impact factor: 9.546

4.  Metformin: historical overview.

Authors:  Clifford J Bailey
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

5.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 6.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Authors:  Vanita R Aroda; William C Knowler; Jill P Crandall; Leigh Perreault; Sharon L Edelstein; Susan L Jeffries; Mark E Molitch; Xavier Pi-Sunyer; Christine Darwin; Brandy M Heckman-Stoddard; Marinella Temprosa; Steven E Kahn; David M Nathan
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 7.  The pharmacogenetics of metformin.

Authors:  Jose C Florez
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 8.  Metformin and ageing: improving ageing outcomes beyond glycaemic control.

Authors:  Willy Marcos Valencia; Ana Palacio; Leonardo Tamariz; Hermes Florez
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 9.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.

Authors:  Yan Zheng; Sylvia H Ley; Frank B Hu
Journal:  Nat Rev Endocrinol       Date:  2017-12-08       Impact factor: 43.330

10.  Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes.

Authors:  Rikke Kruse; Sara G Vienberg; Birgitte F Vind; Birgitte Andersen; Kurt Højlund
Journal:  Diabetologia       Date:  2017-07-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.